Shane J. Schaffer and Dr. Ann Childress, CEO and consultant at Cingulate Inc. CING, respectively, were guest speakers at Benzinga’s All Access on June 3rd, 2022.
Cingulate is a biopharmaceutical company engaging in the research and development of new product candidates for the treatment of central nervous system disorders - specially its innovative Precision Timed Release (PTR) Technology.
Watch the full interview here.
Photo by Mitchell Griest on Unsplash
CINGCingulate Inc
$4.41-6.77%
Edge Rankings
Momentum
23.18
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
